(object) array( 'id' => '3898055', 'url' => 'FR/fixed_interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744254, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105907', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps fixe soit passée depuis le renforcement précédent. Ce programme induit généralement une pause après un renforçateur puis une augmentation progressive du rythme d\'émission des réponses jusqu\'à un niveau élevé au moment où le prochain renforçateur est reçu.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059392, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A schedule in which a person is reinforced for the first response after a fixed period of time has passed since the previous reinforcement. This schedule usually causes people to pause after a reinforcer and then to gradually increase their response rate until they are working at a high rate at the moment they receive the next reinforcer.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed_interval_₁', )

(object) array( 'id' => '6228620', 'url' => 'FR/primary_outcome_measure', 'image' => '', 'title' => 'Critère de jugement principal', 'tags' => array ( 0 => 'Critère de jugement principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critère de jugement principal', 'source_id' => 4011188, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104701', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le critère de jugement défini dans le protocole qui est le plus important pour évaluer l\'effet d\'une intervention. La plupart des études cliniques ont un critère de jugement principal, mais certaines peuvent en avoir plusieurs.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081752334336, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The planned outcome measure in the protocol that is the most important for evaluating the effect of an intervention. Most clinical studies have one primary outcome measure, but some may have more than one.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary outcome measure', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_outcome_measure', )

(object) array( 'id' => '10479588', 'url' => 'FR/Dermokil', 'image' => 'dermokillogo-1359898176.jpg;', 'title' => 'Dermokil', 'tags' => array ( 0 => 'Dermokil', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Dermokil', 'source_id' => 4925105, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083408', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Ezel Kozmetik a été fondée suite à une décision prise par l’homme d’affaire Ünal Karaca après avoir vu que l’on pouvait concevoir des produits cosmétiques à partir de sel de la mer Morte. Sur ce, il décida de produire des produits à base d\'argile qui sont utilisés depuis des siècles en Anatolie et plus récemment partout dans le monde et de promouvoir ses avantages en tant que produits cosmétiques. Les produits Dermokil (Produits Dermoclay) ont vu le jour à l’issue de 2 ans d’étude dans les laboratoires R&D et après les résultats positifs obtenus lors des essais effectués sur 2000 personnes. Les certificats d’enregistrement de marque et les rapports d’approbation établis par l’université Cumhuriyet, les matières premières et les produits ayant des rapports d’analyse microbiologique sont contrôlés par des dispositifs technologiques conformément aux normes nationales et internationales. Les analyses physiques, chimiques et microbiologiques des produits se réalisent d’une manière rapide et sûre à chaque étape de la production. L\'usine d\'Ezel Kozmetik composée d\'installations de production modernes a été établie à Sivas en 2006 et d\'une équipe de R&D composée d’ingénieurs chimistes experts en la matière, vise à devenir une marque leader dans le secteur de la cosmétique à travers ses machines de technologie avancée et son service logistique.', 'usage_comment' => '', 'glossary' => '', 'width' => 300, 'height' => 300, '_version_' => 1507928310837936128, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Dermokil', 'Definition' => 'Ezel Kozmetik was founded when Unal Karaca, the businessman, saw that the cosmetic products were made up of the salt of the Dead Sea and decided to produce the clay products which have been used in Anatolia for centuries and throughout the world during the recent years and to promote its benefits as a cosmetics. The Dermokil products (Dermoclay Products) appeared after testing on 2000 individuals and obtaining positive results and a two-year R&D study. Its brand registration certificates and the reports approved by Cumhuriyet University, the raw materials and products having microbiological analysis report are inspected by technological devices in national and international standards. In every stage of the production, the physical, chemical and microbiological analyses of the products are rapidly and reliably conducted. The factory of Ezel Kozmetik composed of the modern manufacturing plant established in Sivas in 2006 and an R&D team consisting of chemical engineers who are expert in their field aims to go ahead on the road to become a pioneer brand in the cosmetics sector through the high-tech machines and logistics services it provides.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'dermokillogo-1359898176.jpg;', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'dermokil', 'Creation Date' => '2013/2/5', 'Company' => '', 'Synonym' => '', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Dermokil', )

(object) array( 'id' => '7745839', 'url' => 'FR/investigational_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259723, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821506, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'investigational treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'experimental_treatment', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'investigational_treatment', )

(object) array( 'id' => '7745840', 'url' => 'FR/experimental_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259724, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821507, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'experimental treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'experimental_treatment', )

(object) array( 'id' => '3898056', 'url' => 'FR/variable_ratio_₁', 'image' => '', 'title' => 'Proportion variable', 'tags' => array ( 0 => 'Proportion variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Proportion variable', 'source_id' => 3744260, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105908', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme de renforcement basé sur la réponse dans lequel le nombre de réponses requises pour un renforcement varie après que chaque renforçateur est présenté. Le nombre moyen de réponses est utilisé pour indexer le programme. Par exemple, un rat peut appuyer sur un levier de renforcement 50 fois, puis 150, 70, 30, et 200. En ajoutant ces besoins de réponse pour un total de 500, puis en divisant par le nombre de réponses distinctes apportées (5), on obtient la valeur du programme, PV 100. 2) Un programme dans lequel une personne est renforcée en effectuant une réponse seulement après avoir effectué un nombre variable de ces réponses sans renforcement. Ce programme induit généralement un rythme élevé et uniforme. Il produit le plus haut rythme de réponses pour les programmes simples.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059393, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A response-based schedule of reinforcement in which the number of responses required for reinforcement changes after each reinforcer is presented. The average number of responses is used to index the schedule. For example, a rat may press a lever for reinforcement 50 times, then 150, 70, 30, and 200. Adding these response requirements for a total of 500, then dividing by the number of separate response runs (5), yields the schedule value, VR 100. 2) A schedule in which people are reinforced for making a response only after they have made a varying number of those responses without reinforcement. This schedule usually causes people to work at a high and uniform rate of speed. It produces the highest rate of responding of the simple schedules.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'ratio schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable ratio', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_ratio_₁', )

(object) array( 'id' => '7745836', 'url' => 'FR/informed_consent_₇', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 1259720, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus afin de s\'assurer que les patients volontaires comprennent tous les risques associés à la participation à un essai clinique tels que les effets indésirables et choisissent de participer sans coercition ni pression de quiconque. Le chercheur principal ou de ses associés sont tenus d\'expliquer l\'étude attentivement et répondre à toutes les questions d\'un participant avant l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821505, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'informed consent', 'Definition' => 'A process to ensure that patient volunteers understand all the risks associated participating in a clinical trial such as adverse side effects and are choosing to participate without coercion or pressure from anyone. The principal investigator or his or her associates are required to explain the study carefully and answer all questions of a participant before the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₇', )

(object) array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', )

(object) array( 'id' => '6228625', 'url' => 'FR/publications_₂', 'image' => '', 'title' => 'Publications', 'tags' => array ( 0 => 'Publications', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Publications', 'source_id' => 4011325, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110603', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Articles ou résumés scientifiques publiés concernant une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292251885568, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'Published scientific articles or abstracts about a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'publications', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'publications_₂', )

(object) array( 'id' => '6229990', 'url' => 'FR/other_adverse_event', 'image' => '', 'title' => 'Autre événement indésirable', 'tags' => array ( 0 => 'Autre événement indésirable', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Autre événement indésirable', 'source_id' => 4011599, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110608', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un événement indésirable qui n\'est pas un événement indésirable grave.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292252934144, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'An adverse event that is not a serious adverse event.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'other adverse event', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'other_adverse_event', )